Jose M Garcia1. 1. aGeriatric Research, Education and Clinical Center (GRECC), VA Puget Sound Healthcare System bDepartment of Medicine, Division of Gerontology & Geriatric Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Abstract
PURPOSE OF REVIEW: In spite of its relevance, treatments for the cancer anorexia and cachexia syndrome (CACS) are not available. One of the agents that recently reached phase III clinical trials is anamorelin. Its development, along with that of other agents for this indication, will be reviewed here, with a focus on the gaps in the current knowledge and future directions. RECENT FINDINGS: In spite of several targets showing promising results in early development, their difficulties obtaining regulatory approval underscore the need to reconsider the current strategies in drug development and the challenges in the field of CACS. SUMMARY: Further research is needed in order to meet the challenges of developing treatments for CACS. Preclinical studies should expand our understanding about key regulators of appetite, muscle, and energy metabolism in this setting using models that can be translated reliably to humans. Clinical research efforts should focus on validating the entry criteria, endpoints, outcomes, and the potential synergistic effects and interaction between different targets, nutrition, and exercise interventions. Clinical meaningfulness and significance should be taken into account in the design of clinical trials. It is essential that all key stakeholders are included in the design of future strategies.
PURPOSE OF REVIEW: In spite of its relevance, treatments for the cancer anorexia and cachexia syndrome (CACS) are not available. One of the agents that recently reached phase III clinical trials is anamorelin. Its development, along with that of other agents for this indication, will be reviewed here, with a focus on the gaps in the current knowledge and future directions. RECENT FINDINGS: In spite of several targets showing promising results in early development, their difficulties obtaining regulatory approval underscore the need to reconsider the current strategies in drug development and the challenges in the field of CACS. SUMMARY: Further research is needed in order to meet the challenges of developing treatments for CACS. Preclinical studies should expand our understanding about key regulators of appetite, muscle, and energy metabolism in this setting using models that can be translated reliably to humans. Clinical research efforts should focus on validating the entry criteria, endpoints, outcomes, and the potential synergistic effects and interaction between different targets, nutrition, and exercise interventions. Clinical meaningfulness and significance should be taken into account in the design of clinical trials. It is essential that all key stakeholders are included in the design of future strategies.
Authors: José M Garcia; Ralph V Boccia; Charles D Graham; Ying Yan; Elizabeth Manning Duus; Suzan Allen; John Friend Journal: Lancet Oncol Date: 2014-12-16 Impact factor: 41.316
Authors: Christina Wu; Soledad A Fernandez; Tamara Criswell; Tarek A Chidiac; Denis Guttridge; Miguel Villalona-Calero; Tanios S Bekaii-Saab Journal: Pancreas Date: 2013-07 Impact factor: 3.327
Authors: David S Hong; David Hui; Eduardo Bruera; Filip Janku; Aung Naing; Gerald S Falchook; Sarina Piha-Paul; Jennifer J Wheler; Siqing Fu; Apostolia M Tsimberidou; Michael Stecher; Prasant Mohanty; John Simard; Razelle Kurzrock Journal: Lancet Oncol Date: 2014-04-17 Impact factor: 41.316
Authors: W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey Journal: Am J Med Date: 1980-10 Impact factor: 4.965
Authors: J E Beal; R Olson; L Laubenstein; J O Morales; P Bellman; B Yangco; L Lefkowitz; T F Plasse; K V Shepard Journal: J Pain Symptom Manage Date: 1995-02 Impact factor: 3.612
Authors: Tora S Solheim; Barry J A Laird; Trude Rakel Balstad; Guro B Stene; Asta Bye; Neil Johns; Caroline H Pettersen; Marie Fallon; Peter Fayers; Kenneth Fearon; Stein Kaasa Journal: J Cachexia Sarcopenia Muscle Date: 2017-06-14 Impact factor: 12.910
Authors: F Strasser; T A Lutz; M T Maeder; B Thuerlimann; D Bueche; M Tschöp; K Kaufmann; B Holst; M Brändle; R von Moos; R Demmer; T Cerny Journal: Br J Cancer Date: 2008-01-08 Impact factor: 7.640
Authors: Rami Archid; Wiebke Solass; Clemens Tempfer; Alfred Königsrainer; Michael Adolph; Marc A Reymond; Robert B Wilson Journal: Int J Mol Sci Date: 2019-10-31 Impact factor: 5.923
Authors: Haiming Liu; Pu Zang; Ian In-Gi Lee; Barbara Anderson; Anthony Christiani; Lena Strait-Bodey; Beatrice A Breckheimer; Mackenzie Storie; Alison Tewnion; Kora Krumm; Theresa Li; Brynn Irwin; Jose M Garcia Journal: J Cachexia Sarcopenia Muscle Date: 2021-07-15 Impact factor: 12.063